HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
4317studies shown
Showing 241-252 of 4,317
Drug study icon
RecruitingNCT07105111

Valbenazine for ongoing tardive dyskinesia symptoms

About this title

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Read the official source — NCT07105111
Official study title

A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Multiple locations, including Bryant
Schizophrenia, Depression, ...Medication studyAges 18+
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
RecruitingNCT07140913

KarXT with lithium, valproate, or lamotrigine for mania in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Read the official source — NCT07140913
What is this study about?

Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.

Multiple locations, including Bentonville
BipolarityMedication studyAges 18–65
Countries
United States, France, Argentina, + 10 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT07227454

Esketamine for depression

What is this study about?

This study evaluates the safety and effectiveness of Esketamine for people with depression.

Multiple locations, including Birmingham
DepressionMedication studyAges 12–17
Countries
United States, Brazil, Hungary, + 4 others
Sponsor
Janssen Research & Development, LLC
Drug study icon
RecruitingNCT06951698

KarXT for manic episodes in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Read the official source — NCT06951698
What is this study about?

Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.

Multiple locations, including Little Rock
BipolarityMedication studyAges 18–65
Countries
United States, Australia, New Zealand, + 6 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06951711

KarXT for mania in bipolarity: BALSAM-2 study

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Read the official source — NCT06951711
What is this study about?

Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.

Multiple locations, including Little Rock
BipolarityMedication studyAges 18–65
Countries
United States, China, Croatia, + 8 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT07288567

KarXT for schizophrenia

What is this study about?

Researchers are comparing KarXT and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.

Multiple locations, including Anaheim
SchizophreniaMedication studyAges 13–17
Countries
United States, Colombia, Japan, + 1 other
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06882785

KarXT for acute psychosis in Japanese adults with schizophrenia

About this title

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

Read the official source — NCT06882785
What is this study about?

This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.

Multiple locations, including Kōnan
SchizophreniaMedication studyAges 18–65
Countries
Japan
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT07065240

SPT-300 for major depression, with or without anxiety symptoms

About this title

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Read the official source — NCT07065240
What is this study about?

Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.

Multiple locations, including Chino
DepressionMedication studyAges 18–65
Countries
United States, Bulgaria, Czechia, + 4 others
Sponsor
Seaport Therapeutics
Drug study icon
RecruitingNCT06223880

AXS-05 or bupropion to prevent return of depressive symptoms

About this title

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Read the official source — NCT06223880
Official study title

A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms

Multiple locations, including Bellflower
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Axsome Therapeutics, Inc.
Drug study icon
RecruitingNCT07424404

Xanomeline and Trospium Chloride for Schizophrenia

Official study title

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride in Children and Adolescents With Psychiatric Disorders

Multiple locations, including Anaheim
SchizophreniaMedication studyAges 5–17
Countries
United States, Australia, France, + 7 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
RecruitingNCT07196501

Osavampator or placebo to maintain depression treatment response

About this title

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Read the official source — NCT07196501
Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Multiple locations, including Oceanside
DepressionMedication studyAges 18+
Countries
United States, Australia, Canada, + 8 others
Sponsor
Neurocrine Biosciences (Biotech company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.